Risk Models for Pancreatic Cyst Diagnosis

Alice Cattelani; Giampaolo Perri; Giovanni Marchegiani; Roberto Salvia; Stefano Francesco Crinò

doi:10.1016/j.giec.2023.03.011

Risk Models for Pancreatic Cyst Diagnosis

Gastrointest Endosc Clin N Am. 2023 Jul;33(3):641-654. doi: 10.1016/j.giec.2023.03.011. Epub 2023 Apr 24.

Authors

Alice Cattelani¹, Giampaolo Perri¹, Giovanni Marchegiani¹, Roberto Salvia¹, Stefano Francesco Crinò²

Affiliations

¹ Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.
² Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, G.B. Rossi University Hospital, Verona, Italy. Electronic address: stefanofrancesco.crino@aovr.veneto.it.

PMID: 37245940
DOI: 10.1016/j.giec.2023.03.011

Abstract

The overall prevalence of pancreatic cysts (PCs) is high in the general population. In clinical practice PCs are often incidentally discovered and are classified into benign, premalignant, and malignant lesions according to the World Health Organization. For this reason, in the absence of reliable biomarkers, to date clinical decision-making relies mostly on risk models based on morphological features. The aim of this narrative review is to present the current knowledge regarding PC's morphologic features with related estimated risk of malignancy and discuss available diagnostic tools to minimize clinically relevant diagnostic errors.

Keywords: IPMN; Pancreatic cancer; Pancreatic cystic neoplasm.

Publication types

Review

MeSH terms

Biomarkers
Humans
Pancreatic Cyst* / diagnostic imaging
Pancreatic Neoplasms* / diagnosis
Pancreatic Neoplasms* / epidemiology
Pancreatic Neoplasms* / pathology
Precancerous Conditions* / diagnosis

Substances

Biomarkers